Application of prolonged microdialysis sampling in carboplatin-treated cancer patients
Purpose: To better understand the mechanisms underlying (in)sensitivity of tumors to anticancer drugs, assessing intra-tumor drug pharmacokinetics (PKs) could be important. We explored the feasibility of microdialysis in tumor tissue for multiple days in a clinical setting, using carboplatin as model drug. Methods: Plasma and microdialysate samples from tumor and adipose normal tissues were collected up to 47 h after dosing in eight carboplatin-treated patients with an accessible (sub)cutaneous tumor. Results: Pharmacokinetics were evaluable in tumor tissue in 6/8 patients and in adipose normal tissue in 3/8 patients. Concentration-time curves of unbound platinum in both the tissues followed the pattern of the curves in plasma, with exposure ratios of tissue versus plasma ranging from 0.64 to 1.46. Conclusions: Microdialysis can be successfully employed in ambulant patients for multiple days, which enables one to study tissue PK of anticancer drugs in normal and malignant tissues in more detail.
|Keywords||Carboplatin, Clinical oncology, Microdialysis, Pharmacokinetics, Target site|
|Persistent URL||dx.doi.org/10.1007/s00280-008-0898-0, hdl.handle.net/1765/24169|
Konings, I.R.H.M, Engels, F.K, Sleijfer, S, Verweij, J, Wiemer, E.A.C, & Loos, W.J. (2009). Application of prolonged microdialysis sampling in carboplatin-treated cancer patients. Cancer Chemotherapy and Pharmacology, 64(3), 509–516. doi:10.1007/s00280-008-0898-0